Welcome to our dedicated page for Cartesian Therapeutics SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cartesian Therapeutics, Inc. filings document the regulatory disclosures of a late clinical-stage biotechnology company developing cell therapy candidates for autoimmune diseases. Recent Form 8-K reports furnish quarterly and annual financial results, business updates, corporate slide presentations, and clinical disclosures for Descartes-08, including autoimmune indications such as generalized myasthenia gravis, myositis, juvenile dermatomyositis and systemic lupus erythematosus.
Proxy materials cover director elections, board committee service, executive compensation, equity awards and other governance matters. Additional 8-K filings report board changes and compensatory arrangements, while the company's disclosures also describe cash resources, FDA designations, forward-looking statements and equity incentive activity tied to its common stock.
Cartesian Therapeutics, Inc. reported full year 2025 results and a business update centered on its Descartes-08 cell therapy pipeline. The company ended December 31, 2025 with approximately $126.9 million in cash, cash equivalents and restricted cash, which it expects to fund planned operations into mid-2027, including completion of the Phase 3 AURORA trial.
Total 2025 revenue was $2.8 million, down from $38.9 million in 2024, reflecting much lower collaboration and license revenue. Research and development expenses rose to $58.0 million and general and administrative expenses to $31.5 million. An impairment charge of $56.7 million contributed to a larger net loss of $130.3 million, or $5.02 per basic share, compared with a $77.4 million loss in 2024.
Clinically, enrollment is progressing in the Phase 3 AURORA trial in myasthenia gravis, which plans to enroll about 100 patients and was highlighted by Nature Medicine as a trial to watch in 2026. A Phase 2 TRITON trial in myositis is expected to start in the first half of 2026, while the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis is actively enrolling. Descartes-08 has received multiple U.S. FDA designations, and recent Nature Medicine publications described its mechanism of action and 12‑month response data. Leadership changes included adding cell therapy veteran Adrian Bot, M.D., Ph.D., to the board and appointing CEO Carsten Brunn, Ph.D., as chairman.
FMR LLC has filed Amendment No. 3 to a Schedule 13G reporting its beneficial ownership of 1,366,989 shares of Cartesian Therapeutics Inc. common stock, representing 5.3% of the class as of December 31, 2025. FMR reports sole voting power over 1,366,854 shares and sole dispositive power over 1,366,989 shares. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 1,366,989 shares and no voting power, reflecting her control position in FMR. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cartesian Therapeutics.
An insider of RNAC, identified as Christopher M. Jewell, filed a Rule 144 notice to sell 9,000 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value listed as $68,940.00 and total shares outstanding shown as 26,003,606. The shares to be sold were acquired on 01/10/2025 by exercising options under a registered plan for cash. Over the prior three months, the same seller reported additional common stock sales of 17,935 shares on 11/19/2025 for $129,587.55 and 10,510 shares on 01/09/2026 for $84,256.57, indicating ongoing liquidation of a portion of their position.
RNAC filed a Rule 144 notice for an insider stock sale. Christopher M. Jewell plans to sell 1,510 shares of RNAC common stock through Morgan Stanley Smith Barney on or about 01/09/2026 on the NASDAQ market. The planned sale has an aggregate market value of $12,105.37, based on the price at the time of the notice, and is against a backdrop of 26,003,606 common shares outstanding.
The 1,510 shares to be sold were acquired on 01/02/2026 through the vesting of restricted stock under a registered plan, in exchange for services rendered to the company. The notice also reports that Jewell previously sold 17,935 common shares on 11/19/2025, generating gross proceeds of $129,587.55.
Cartesian Therapeutics, Inc. filed a current report to furnish new investor materials. The company is making available a corporate slide presentation it uses at industry and investor conferences, attached as Exhibit 99.1, which provides updates and summaries of its business.
The company also issued a press release on January 9, 2026 highlighting recent progress and outlining its 2026 outlook, attached as Exhibit 99.2. These materials are furnished under Regulation FD, not deemed “filed” for liability purposes, and are not incorporated into other securities law filings unless specifically referenced.
Cartesian Therapeutics President and CEO Carsten Brunn reported a sale of company common stock. On 01/06/2026, he sold 23,766 shares of Cartesian Therapeutics, Inc. (RNAC) common stock at a price of $6.8197 per share.
According to the footnote, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. After this transaction, Brunn directly beneficially owned 323,530 shares of Cartesian Therapeutics common stock.
Cartesian Therapeutics Chief Medical Officer Milos Miljkovic reported a small sale of company stock tied to equity compensation taxes. On 01/06/2026, he sold 3,573 shares of Cartesian Therapeutics, Inc. common stock at a price of $6.8197 per share. According to the footnote, the shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, rather than as a discretionary open-market sale. After this transaction, he continued to beneficially own 58,820 shares of common stock in direct ownership.
Cartesian Therapeutics, Inc. reported an insider transaction by its Chief Financial Officer, Blaine Davis. On 01/06/2026, Davis sold 10,591 shares of the company’s common stock at an average price of $6.8197 per share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees, indicating a tax-related sale rather than a discretionary open-market reduction in holdings. Following this transaction, Davis beneficially owned 121,220 shares of Cartesian Therapeutics common stock directly.
Cartesian Therapeutics director Patrick Zenner reported new equity awards. On January 2, 2026, he acquired 2,600 shares of common stock at a price of $0, representing restricted stock units that will vest in full on January 2, 2027. On the same date, he was granted a stock option for 7,800 shares of common stock at an exercise price of $6.76 per share, first exercisable on January 2, 2027 and expiring on January 1, 2036. After these transactions, he directly beneficially owned 12,974 shares of common stock and 7,800 stock options.
Cartesian Therapeutics Chief Operations Officer Emily English reported new equity awards in the company’s stock. On January 2, 2026, she received 24,000 shares of common stock at a price of $0, bringing her directly owned common stock holdings to 94,226 shares.
On the same date, she was granted an employee stock option for 71,000 shares of common stock at an exercise price of $6.76 per share, expiring on January 1, 2036. The restricted stock units vest 25% on January 2, 2027, with the rest vesting in three equal annual installments through January 2, 2030, while the option vests 25% on January 2, 2027, and the remaining 75% in 36 equal monthly installments thereafter.